RA CAPITAL MANAGEMENT, L.P. - 04 Jun 2025 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
TYRA
Transactions as of
04 Jun 2025
Net transactions value
+$11,751,304
Form type
4
Filing time
06 Jun 2025, 16:43:19 UTC
Previous filing
02 Jun 2025
Next filing
09 Jun 2025

Reporting Owners (5)

Name Relationship Address Signature Signature date CIK
RA CAPITAL MANAGEMENT, L.P. Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P. 06 Jun 2025 0001346824
RA Capital Healthcare Fund LP Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P. 06 Jun 2025 0001315082
RA Capital Nexus Fund, L.P. Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund GP, LLC the General Partner of RA Capital Nexus Fund, L.P. 06 Jun 2025 0001780117
Kolchinsky Peter Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, individually 06 Jun 2025 0001384859
Shah Rajeev M. Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Rajeev Shah, individually 06 Jun 2025 0001619841

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Purchase $9,609,430 +997,864 +11% $9.63 9,695,820 04 Jun 2025 See footnotes F1, F2, F3
transaction TYRA Common Stock Purchase $2,141,873 +213,334 +2.2% $10.04 9,909,154 05 Jun 2025 See footnotes F2, F3, F4
holding TYRA Common Stock 1,496,613 04 Jun 2025 See footnotes F3, F5
holding TYRA Common Stock 442,721 04 Jun 2025 See footnotes F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.32 to $10.15 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 These securities are held directly by the Nexus Fund.
F6 These securities are held directly by the Account.

Remarks:

Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.